Effect of alendronate on pseudomembrane cytokine expression in patients with aseptic osteolysis.
To determine whether alendronate alters the pseudomembrane inflammatory cytokine profile in patients with established aseptic osteolysis. A prospective, double-blind, randomized, controlled trial was conducted. Ten individuals listed for revision surgery for aseptic failure of a primary cemented arthroplasty were randomly assigned placebo/alendronate 70 mg once weekly for 8 weeks before revision surgery. Formalin-preserved pseudomembrane samples were paraffin-sectioned for immunohistochemical analysis to assess inflammatory cytokine protein expression. Polymerase chain reaction was carried out to assess expression of relevant mRNA. No significant difference was detected in the inflammatory cytokine protein or mRNA expression between groups. Alendronate 70 mg administered for an 8-week period before surgery did not alter the pseudomembrane inflammatory cytokine profile in patients with established aseptic osteolysis. Any potential biological effects may occur due to downstream effects on osteoclast and osteoblast function.
Holt
Graeme
G
Department of Orthopaedic and Trauma Surgery, Southern General Hospital, Glasgow, United Kingdom.
Reilly
James
J
Meek
R M Dominic
RM
D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism*; D004311:Double-Blind Method; D005260:Female; D006621:Hip Joint / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008566:Membranes / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D010014:Osteolysis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D012086:Reoperation
D050071:Bone Density Conservation Agents; D016207:Cytokines; D019386:Alendronate